[1] Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update[J]. J Hepatol, 2021, 74(5):1212-1224. [2] Calderaro J, Ghaffari Laleh N, Zeng Q, et al. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma[J]. Nat Commun, 2023, 14(1):8290. [3] 葛轩云, 张苗苗, 黄炳银, 等. 混合型肝细胞癌-胆管癌的临床病理学特征及研究进展[J]. 临床与实验病理学杂志, 2023, 39(2):216-219. [4] Choi J H, Ro J Y. Combined hepatocellular-cholangiocarcinoma: an update on pathology and diagnostic approach[J]. Biomedicines, 2022, 10(8):1826. [5] Ye L, Schneider J S, Ben Khaled N, et al. Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management[J]. Liver Cancer, 2023, 13(1):6-28. [6] Chu K J, Lu C D, Dong H, et al. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases[J]. Eur J Gastroenterol Hepatol, 2014, 26(2):192-199. [7] Ye J, Xie X, Liu B, et al. Imaging features on contrast-enhanced ultrasound and clinical characteristics of hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: comparison with hepatitis B virus-related hepatocellular carcinoma[J]. Ultrasound Med Biol, 2017, 43(11):2530-2536. [8] Zheng C, Gu X T, Huang X L, et al. Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study[J]. Radiol Med, 2023, 128(12):1460-1471. [9] Zhou Y, Yin S, Zhao L, et al. CEUS and CT/MRI LI-RADS in association with serum biomarkers for differentiation of combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma[J]. Front Oncol, 2022, 12:897090. [10] Sciarra A, Park Y N, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma[J]. Hum Pathol, 2020, 96:48-55. [11] Taghavi S A, Eshraghian A, Niknam R, et al. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(6):575-584. [12] Fung B M, Tabibian J H. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(5):487-496. [13] Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma[J]. Acta Pharm Sin B, 2022, 12(2):558-580. [14] 王钲钰, 夏冬东, 韩国宏. 《2023年美国肝病学会实践指南:肝细胞癌预防、诊断和治疗》要点摘译[J]. 中华肝脏病杂志, 2023, 31(12):1262-1265. [15] Hu X, Chen R, Wei Q, et al. The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we?[J]. Int J Biol Sci, 2022, 18(2):536-551. [16] Zhang M, Liu K, Zhang Q, et al. Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells[J]. Front Immunol, 2023, 14:1081572. [17] 中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版). 中华肝脏病杂志, 2021, 29(10):948-966. [18] Uesaka K. Left hepatectomy or left trisectionectomy with resection of the caudate lobe and extrahepatic bile duct for hilar cholangiocarcinoma (with video)[J]. J Hepatobiliary Pancreat Sci, 2012, 19(3):195-202. [19] Farazi P A, Zeisberg M, Glickman J, et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice[J]. Cancer Res, 2006, 66(13):6622-6627. [20] Ding G Y, Ma J Q, Yun J P, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma[J]. J Hepatol, 2022, 76(3):608-618. [21] Chen Y, Xu Y, Zhang Y. Current status of laparoscopic radical hilar cholangiocarcinoma in Mainland China[J]. Biosci Trends, 2020, 14(3):168-173. |